Buy Flunitrazolam Pellets (0.25 mg) for Advanced Laboratory Research in Europe

Flunitrazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-triazolo[1,5-a]benzodiazepine) represents a critical triazolobenzodiazepine reference compound for contemporary forensic toxicology, analytical chemistry, and pharmacological investigations across European laboratories. As the definitive EU source for rigorously characterised research chemicals, Pure Lab Chems .eu supplies Flunitrazolam pellets (0.25 mg per pellet) exclusively to qualified analytical chemists, biochemists, pharmacologists, and laboratory managers engaged in controlled in vitro research, mass spectral method validation, and GABA_A receptor binding studies within institutional frameworks.fishersci+2

Uncompromising Purity and Analytical Characterisation

Every batch of Flunitrazolam pellets supplied by Pure Lab Chems .eu is guaranteed to achieve a minimum purity of ≥99.0%, as verified by reverse-phase high-performance liquid chromatography (RP-HPLC) with ultraviolet detection at 230 nm and 280 nm. This purity specification is not merely a numerical target; it represents the foundation upon which reproducible, publishable research outcomes depend. Each shipment is accompanied by a comprehensive Certificate of Analysis (CoA) that documents batch-specific HPLC chromatograms, retention time confirmation against certified reference standards, and quantitative impurity profiling with identification of any related benzodiazepine analogues or synthetic intermediates.

The CoA further includes residual solvent analysis conducted in accordance with ICH Q3C guidelines, ensuring that levels of dichloromethane, acetonitrile, methanol, and other process-related solvents remain below permitted daily exposure limits. Heavy metal content (lead, cadmium, mercury, arsenic) is verified by inductively coupled plasma mass spectrometry (ICP-MS) and reported at parts-per-million levels, typically below 10 ppm for each element. These stringent specifications distinguish our analytical-grade material from lower-grade industrial reagents that may contain uncharacterised impurities capable of confounding mass spectral interpretations or cellular assay results.

Flunitrazolam pellets (0.25 mg) are supplied as compressed, uniform micro-tablets exhibiting an off-white to white appearance, consistent with the physical characteristics of triazolobenzodiazepine compounds. This physical form is verified through visual inspection under controlled lighting conditions and documented in the CoA with high-resolution imagery. The pellet format ensures precise mass delivery (0.25 mg ±0.01 mg per pellet) for stock solution preparation, eliminates the need for manual weighing of sub-milligram quantities (which is prone to significant error), and facilitates rapid dissolution in appropriate solvents for in vitro applications. For laboratory managers procuring reference standards for LC-MS/MS library development or proficiency testing schemes targeting novel psychoactive substances (NPS), this level of physical and chemical characterisation is non-negotiable.

Principal Laboratory Applications and Research Methodologies

Analytical Toxicology & Forensic Chemistry: Flunitrazolam serves as a certified reference material (CRM) for mass spectral library development in LC-MS/MS and GC-MS platforms used by forensic toxicology laboratories across the EU. As a potent triazolobenzodiazepine analogue of flunitrazepam, Flunitrazolam has emerged as a relevant compound in drug-facilitated sexual assault (DFSA) investigations, driving under the influence of drugs (DUID) cases, and post-mortem toxicology screenings. The compound’s characteristic fragmentation pattern under electrospray ionisation (ESI) and electron impact (EI) conditions enables unambiguous identification in complex biological matrices during method validation for toxicological screenings. The presence of the fluorine atom and triazolo ring fusion provides distinctive mass spectral signatures that facilitate detection in high-resolution mass spectrometry (HRMS) workflows. Laboratories participating in proficiency testing schemes utilise Flunitrazolam reference standards (0.25 mg pellets) to calibrate instrumentation, verify extraction recovery rates, and establish limits of detection (LOD) and quantification (LOQ) for novel benzodiazepine analogues.

Chemical Synthesis & Reaction Monitoring: As a high-purity triazolobenzodiazepine building block, Flunitrazolam functions as a reference standard for monitoring synthetic transformations in medicinal chemistry research programmes focused on novel GABA_A receptor modulators and anxiolytic analogues. The compound’s well-defined IUPAC structure (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-triazolo[1,5-a]benzodiazepine) provides a stable benchmark against which reaction intermediates and analogues are compared via NMR spectroscopy (particularly ¹⁹F NMR) and HPLC retention time matching. Synthetic chemists developing novel GABA_A receptor ligands rely on Flunitrazolam’s consistent chromatographic behaviour to validate new purification protocols and establish structure-activity relationships (SAR) within the triazolobenzodiazepine class, particularly in relation to structurally similar compounds such as flunitrazepam, alprazolam, triazolam, etizolam, and clonazolam.fishersci+2

Pharmacological In Vitro Assays: Within controlled laboratory environments, Flunitrazolam is employed in receptor-binding and functional assays using recombinant GABA_A receptor subtypes expressed in mammalian cell lines. The compound serves as a reference standard in competitive binding assays, enabling determination of Ki and IC₅₀ values for novel GABA_A receptor positive allosteric modulators (PAMs). Flunitrazolam acts primarily as a high-affinity agonist at the benzodiazepine binding site of GABA_A receptors, exhibiting potent anxiolytic, sedative, and muscle relaxant properties in preclinical models, making it a valuable tool for neurochemical and SAR studies. The triazolo ring fusion enhances metabolic stability and receptor affinity relative to classical 1,4-benzodiazepines, providing critical insights into the pharmacokinetic properties of triazolobenzodiazepine analogues. Cellular uptake assays utilise Flunitrazolam to investigate transporter-mediated flux across blood-brain barrier models, while metabolic stability profiling in primary hepatocyte cultures or liver microsomes establishes intrinsic clearance rates for structure-activity relationship (SAR) investigations. All such applications are strictly limited to in vitro modelling and must be conducted by qualified personnel within appropriate institutional frameworks (university, CRO, or pharmaceutical R&D).

Quality Control & Method Validation: Pharmaceutical quality control laboratories utilise Flunitrazolam reference standards (0.25 mg pellets) to validate analytical methods for detecting benzodiazepine impurities and novel psychoactive substances in drug substance and drug product matrices. The compound’s well-characterised UV absorption spectrum (λmax approximately 230 nm and 280 nm) enables spectrophotometric quantification during assay development, while its stability under accelerated conditions (40°C/75% RH) supports forced degradation studies for regulatory submissions. Flunitrazolam is particularly valuable for validating methods targeting emerging benzodiazepine analogues in seized materials and biological samples, including differentiation from closely related triazolobenzodiazepines and classical 1,4-benzodiazepines.

Pellet Format Advantages and Handling Protocols

The 0.25 mg pellet format offers distinct advantages over traditional powder formulations for laboratory reference standards, particularly for high-potency compounds where sub-milligram accuracy is critical. Each pellet contains a precisely measured 0.25 mg of Flunitrazolam (±0.01 mg tolerance), eliminating weighing errors associated with microbalances and reducing operator exposure to fine particulate matter. Pellets are individually wrapped in aluminium foil or sealed in amber vials to protect from light and moisture, ensuring stability during storage and transport. For stock solution preparation, a single 0.25 mg pellet can be dissolved directly in 1 mL of methanol or DMSO to yield a 0.25 mg/mL stock solution (approximately 0.66 mM; molecular weight 381.81 g/mol), or in 10 mL to yield 0.025 mg/mL (approximately 0.066 mM), streamlining workflow and minimising handling time.

Flunitrazolam pellets exhibit moderate susceptibility to photolytic degradation and oxidative breakdown, necessitating strict storage protocols to maintain analytical integrity over extended periods. Pellets should be stored at -20°C in amber glass vials with PTFE-lined caps or in original light-resistant packaging, protected from light and maintained under desiccated conditions (relative humidity <10%) or under inert atmosphere (nitrogen or argon) to prevent oxidative degradation. For short-term use (up to 30 days), storage at +4°C in a dedicated laboratory refrigerator is acceptable, provided the packaging remains sealed and protected from ambient light. Long-term archival storage (-80°C under inert atmosphere) is recommended for reference standards intended for multi-year use in proficiency testing or inter-laboratory comparisons.

Critical safe handling prerequisites mandate that all manipulations of Flunitrazolam pellets occur within a certified chemical fume hood operating at a face velocity of 0.5 m/s or greater. Personnel must wear nitrile gloves (tested to EN 374 standards), safety goggles with side shields, and a laboratory coat compliant with EN 14126. Although the pellet format minimises airborne particulate exposure compared to powder, a certified particulate respirator (EN 149 FFP2 or higher) is recommended when crushing or dissolving pellets to prevent inhalation exposure. For stock solution preparation, Flunitrazolam demonstrates solubility in dimethyl sulfoxide (DMSO) to 10 mM, in methanol to approximately 5 mM, in anhydrous ethanol to 5 mM, and sparingly soluble in aqueous buffers; solutions should be prepared fresh daily or stored at -20°C in amber vials for no more than 7 days to prevent oxidative degradation.

Technical Specifications and Molecular Attributes

Pure Lab Chems .eu: Your Premier EU Vendor for High-Purity Reagents

Pure Lab Chems .eu transcends the conventional supplier role to serve as an indispensable partner in European scientific rigour. Our ISO 9001-certified quality management system governs every stage of material procurement, from batch selection through final CoA issuance, ensuring that each Flunitrazolam pellet batch (0.25 mg) meets the exacting standards demanded by analytical chemists and laboratory managers across all 27 EU member states. Our dedicated logistics chain employs temperature-controlled, discreet packaging with real-time tracking, guaranteeing that reference standards arrive in pristine condition regardless of destination—from Berlin to Barcelona, from Dublin to Athens.

Beyond logistics, Pure Lab Chems .eu distinguishes itself through expert customer support staffed by chemists capable of discussing analytical specifications, method validation requirements, and CoA interpretation. Whether you require guidance on HPLC method parameters for Flunitrazolam quantification or need clarification on residual solvent limits for your specific application, our technical team provides responsive, scientifically grounded assistance. We do not merely sell chemicals; we enable critical research outcomes by supplying rigorously tested, fully documented materials that form the foundation of trustworthy, reproducible science.